Changes in the Use of Montelukast for Asthma After a US Food and Drug Administration Boxed Warning - Top-Institutions - MDSpire

Changes in the Use of Montelukast for Asthma After a US Food and Drug Administration Boxed Warning

  • By

  • Hariharan Shanmugam

  • Aaron S. Kesselheim

  • Ian T. T. Liu

  • William B. Feldman

  • Benjamin N. Rome

  • May 22, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Mass General Brigham
    Mass General Brigham

    Boston, MA

    Key Differentiators

    • Pulmonology

  • #2

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Pulmonology

  • #3

    University of Michigan
    University of Michigan

    Ann Arbor, MI

    Key Differentiators

    • Pulmonology

  • #4

    Changi General Hospital
    Changi General Hospital

    Singapore, SG

    Key Differentiators

    • Pulmonology

  • #5

    Keck Medicine of USC
    Keck Medicine of USC

    Los Angeles, CA

    Key Differentiators

    • Pulmonology

Original Source(s)

Changes in the Use of Montelukast for Asthma After a US Food and Drug Administration Boxed Warning

  • by Hariharan Shanmugam, Aaron S. Kesselheim, Ian T. T. Liu, William B. Feldman, Benjamin N. Rome

  • May 22, 2026

Related Content

Studies on allergic diseases and B cells in the past 20 years: a bibliometric analysis via CiteSpace and VOSviewer

Paradoxical enrichment of Akkermansia in children with poorly controlled asthma: a longitudinal study

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.